Worldwide Initiative for Diabetes Education symposium in partnership with Diabetes Kongress 2020 DDG
The treatment of type 2 diabetes mellitus has evolved in the present century toward safer and more effective treatments, which in some cases can also reduce the risk of hypoglycemia, and cardiovascular disease. New glucose-lowering drugs acting on novel pathways, as well as new formulations, have been developed, licensed and launched, many of which provide new options for the management of type 2 diabetes. However, there is a rising prevalence of type 2 diabetes and its associated comorbidities, posing new challenges for health care practitioners.
This interactive virtual symposium will begin with a global review of type 2 diabetes mellitus and then address the risks of hypoglycemia and treatment approaches that lower these risks. Evidenced-based data on combination therapy will also be discussed, along with how clinical inertia can be best managed. Finally, a review of the new therapies, and how to optimize results during the COVID-19 pandemic will be presented.
At the conclusion of the virtual program, participants will be able to:
• Recognize the association between glycemic variability as a predictor of hypoglycemia, the
clinical implications of hypoglycemia in type 2 diabetes patients, and proven approaches to
• Explain the role of fixed dose combination therapy and when and how it is appropriate to
adjust insulin therapy in type 2 diabetes patients, as well as manage clinical inertia
• Implement new treatment strategies with evidence provided by recent cardiovascular
outcomes trials that highlight new therapies that have a demonstrated decrease in
cardiovascular risk, especially during the COVID-19 pandemic.
Introduction and program objectives
Global overview of type 2 diabetes
Proven approaches to preventing Hypoglycaemia
Fixed dose combinations and other strategies to managing type 2 diabetes
New type 2 diabetes treatment options: optimizing results amidst the COVID-19 Pandemic
Discussion & Questions